Filters

Term Search
You can select from the dropdown list OR enter your own terms to refine the search.

Last Updated: 01/07/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications

Deuruxolitinib (Leqselvi) for severe alopecia areata.

Deuruxolitinib (Leqselvi) for severe alopecia areata.

Journal: The Medical letter on drugs and therapeutics
Published: October 21, 2025

Episodic Neuropathic-Like Musculoskeletal Pain Associated With Ritlecitinib Therapy in Alopecia Universalis: A Case Report.

Episodic Neuropathic-Like Musculoskeletal Pain Associated With Ritlecitinib Therapy in Alopecia Universalis: A Case Report.

Journal: Cureus
Published: October 14, 2025

Treatment of alopecia areata with JAK inhibitors: a review of the literature.

Treatment of alopecia areata with JAK inhibitors: a review of the literature.

Journal: Acta dermatovenerologica Alpina, Pannonica, et Adriatica
Published: August 25, 2025

Comparative Efficacy of Janus Kinase Inhibitors Indicated for Severe Alopecia Areata: A Bayesian Network Meta-Analysis and Matching-Adjusted Indirect Comparison.

Comparative Efficacy of Janus Kinase Inhibitors Indicated for Severe Alopecia Areata: A Bayesian Network Meta-Analysis and Matching-Adjusted Indirect Comparison.

Journal: The Journal of dermatology
Published: August 04, 2025

Association of Janus kinase inhibitors with reduced depression in alopecia areata.

Association of Janus kinase inhibitors with reduced depression in alopecia areata.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: July 25, 2025

Evaluating Current and Emergent JAK Inhibitors for Alopecia Areata: A Narrative Review.

Evaluating Current and Emergent JAK Inhibitors for Alopecia Areata: A Narrative Review.

Journal: Dermatology and therapy
Published: June 29, 2025

Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients.

Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients.

Journal: Frontiers in medicine
Published: June 04, 2025

Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial.

Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial.

Journal: Journal of the American Academy of Dermatology
Published: April 10, 2025

JAK Inhibitors and Inflammatory Nail Disorders: A Systematic Review of Clinical Outcomes and Therapeutic Potential.

JAK Inhibitors and Inflammatory Nail Disorders: A Systematic Review of Clinical Outcomes and Therapeutic Potential.

Journal: American journal of clinical dermatology
Published: March 31, 2025

Properties of FDA-approved small molecule protein kinase inhibitors: A 2025 update.

Properties of FDA-approved small molecule protein kinase inhibitors: A 2025 update.

Journal: Pharmacological research
Published: March 29, 2025

Janus kinase inhibitors for alopecia areata: a review of clinical data.

Janus kinase inhibitors for alopecia areata: a review of clinical data.

Journal: Frontiers in immunology
Published: February 17, 2025

Safety of oral JAK inhibitors in treating alopecia areata: a systematic review and network meta-analysis.

Safety of oral JAK inhibitors in treating alopecia areata: a systematic review and network meta-analysis.

Journal: Frontiers in pharmacology
Published: February 14, 2025
Showing 1-12 of 27

Last Updated: 01/07/2026